Radiation Therapy in Unresectable Gall Bladder Cancer

The goal of this clinical trial is to compare two treatment regimes, namely, systemic therapy (chemotherapy and/or immunotherapy) alone vs. systemic therapy and radiation therapy in patients with inoperable but localized gallbladder cancer. The main questions it aims to answer are: * Whether adding radiation therapy to systemic therapy improves overall survival? * What are the effects on other endpoints like cancer-free intervals, side effects, and quality of life? Participants will be randomly assigned to one of the two treatment regimes mentioned earlier by a computer-based program. Researc

Trial Details

NCT ID
NCT06214572
Phase
PHASE2 / PHASE3
Sponsor
Tata Memorial Centre
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Systemic therapy (Gemcitabine plus Cisplatin)
  • RT
  • Systemic therapy (Gemcitabine plus oxaliplatin)
  • Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)
  • Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)
Locations (sample)
  • Mumbai, Maharashtra, India|19.07283,72.88261

Key Eligibility Criteria

  • Histologically proven (biopsy/cytology) adenocarcinoma of gall bladder. Gall bladder neck primaries with hilar block mimicking hilar cholangiocarci…
  • Non metastatic at presentation as determined using cross sectional imaging and diagnostic laparoscopy if done as a part of standard work up recomme…
  • Locally advanced disease with one or more of the following
  • Extensive liver infiltration not amenable for surgery but feasible for safe radiation delivery (Liver minus gross tumor volume at least 700cc)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →